L'Oreal says weight loss drugs are impacting beauty and skin care sales
L'Oreal reports 7.7% sales growth, attributing part of the increase to the rise in use of GLP-1 drugs, which have led to significant weight loss and side effects like loose skin.
Intelligence analysis by Qwen 2.5 (3B)
Beauty giant L'Oreal notes that the use of weight loss drugs, known as GLP-1s, has affected sales in beauty and skin care products, prompting the company to develop new products to address side effects like loose skin.
L'Oreal is a big company that makes beauty products. They noticed that some people who take special medicines to lose weight are getting their skin to sag. So L'Oreal made new products to help fix that.
Analysis
{"subheading":"The Rise of GLP-1 Drugs","content":["GLP-1 drugs, such as Ozempic, Wegovy, and Mounjaro, have become popular for treating diabetes and have also been found to cause significant weight loss.","This weight loss has led to a noticeable side effect of loose skin, particularly around the face, for some users.","L'Oreal has responded by developing products to address this issue, including SkinCeuticals and Kiehl's brands."]}
Key points
- L'Oreal reported 7.7% sales growth in the third quarter.
- GLP-1 drugs have led to significant weight loss and side effects like loose skin.
- L'Oreal is developing products to address the side effects of GLP-1 drugs.
The rise in GLP-1 drug use could lead to new opportunities for L'Oreal to develop and sell products that address the side effects of weight loss.
If the side effects of GLP-1 drugs become more common, it could hurt L'Oreal's sales if they don't have products to address these issues.
